HKPD (Cellyan Biotechnology Co) Other Long Term Assets: $-0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKPD Cellyan Biotechnology Co Ltd HKPD
18 GF Score
Price $0.12
! 4 Warning Signs
View Full Analysis

What is Cellyan Biotechnology Co Other Long Term Assets?

Cellyan Biotechnology Co HKPD +1.96% 18 Other Long Term Assets is $-0.00 Mil as of Mar. 2026. GuruFocus rates HKPD with a GF Score™ of 18/100. The stock has 4 warning signs investors should review.

Cellyan Biotechnology Co's other long-term assets for the quarter that ended in Mar. 2026 was $-0.00 Mil.

Cellyan Biotechnology Co's quarterly other long-term assets increased from Mar. 2025 ($-0.00 Mil) to Sep. 2025 ($-0.00 Mil) but then stayed the same from Sep. 2025 ($-0.00 Mil) to Mar. 2026 ($-0.00 Mil).

Cellyan Biotechnology Co's annual other long-term assets increased from Mar. 2024 ($-0.00 Mil) to Mar. 2025 ($-0.00 Mil) but then declined from Mar. 2025 ($-0.00 Mil) to Mar. 2026 ($-0.00 Mil).

Cellyan Biotechnology Co Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Cellyan Biotechnology Co's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cellyan Biotechnology Co Other Long Term Assets Chart

Cellyan Biotechnology Co Annual Data
Trend Mar23 Mar24 Mar25 Mar26
Other Long Term Assets
0.00 -0.00 -0.00 -0.00

Cellyan Biotechnology Co Semi-Annual Data
Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Other Long Term Assets Get a 7-Day Free Trial -0.00 0.00 -0.00 -0.00 -0.00
HKPD
18GF Score
Cellyan Biotechnology Co Ltd HKPD
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cellyan Biotechnology Co Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of $-0.00 Mil mean?
Cellyan Biotechnology Co (HKPD) has a Other Long Term Assets of $-0.00 Mil as of Mar. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Cellyan Biotechnology Co and its competitors.
Is Cellyan Biotechnology Co's Other Long Term Assets too high?
Cellyan Biotechnology Co's current Other Long Term Assets is $-0.00 Mil. Overall, Cellyan Biotechnology Co has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Cellyan Biotechnology Co's Other Long Term Assets compare to COSM and YI?
Cellyan Biotechnology Co's Other Long Term Assets of $-0.00 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Medical Distribution company?
A good Other Long Term Assets depends on the Medical Distribution industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Cellyan Biotechnology Co and its competitors. Cellyan Biotechnology Co's current Other Long Term Assets is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellyan Biotechnology Co stock overvalued right now?
Cellyan Biotechnology Co (HKPD) has a current Other Long Term Assets of $-0.00 Mil. The current Other Long Term Assets is $-0.00 Mil. Cellyan Biotechnology Co's overall GF Score™ is 18/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Cellyan Biotechnology Co (HKPD), the current Other Long Term Assets is $-0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cellyan Biotechnology Co Business Description

Address 13 Ko Fai Road, Room B1, 5th Floor, Well Town Industrial Building, Yau Tong, Kowloon, Hong Kong, HKG
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
18GF Score

Get the complete analysis for HKPD

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.12
Price